Nilotinib hydrochloride (oral gavage, 40 mg/kg, daily, 4 weeks) shows equivalent or higher antitumor effects in BALB/cSLc-nu/nu mice with GIST xenograft[2].
Nilotinib hydrochloride has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model while decreases the PDGFR α and β levels and apoptotic scores in the colon[3].
| Animal Model: | BALB/cSLc-nu/nu mice with GIST xenograft (GK1X, GK2X and GK3X)[2] |
| Dosage: | 40 mg/kg |
| Administration: | Oral gavage; daily; 4 weeks |
| Result: | Inhibited tumor growth by 69.6% in GK1X, 85.3% in GK2X and 47.5% in GK3X xenograft line. |